Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer Corrigendum in /10.3892/etm.2022.11365

Li,Xinpeng; Yuan,Naxin; Lin,Lingdan; Yin,Lixia; Qu,Yiqing

doi:10.3892/etm.2018.6274

Targeting cysteine‑rich angiogenic inducer‑61 by antibody immunotherapy suppresses growth and migration of non‑small cell lung cancer

Corrigendum in: /10.3892/etm.2022.11365

Authors:
- Xinpeng Li
- Naxin Yuan
- Lingdan Lin
- Lixia Yin
- Yiqing Qu
View Affiliations

Affiliations: Department of Respiration, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China, Department of Respiration, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China, Department of Cardiology, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China
Published online on: June 8, 2018 https://doi.org/10.3892/etm.2018.6274
Pages: 730-738
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is the most frequent type of human lung cancer; lung cancer is responsible for the highest rates of cancer‑associated mortality in the world. Cysteine‑rich angiogenic inducer‑61 (CYR‑61) has been identified as a tumorigenesis‑, development‑ and metastasis‑related gene, and is reported to enhance proliferation, migration and invasion through hepatocyte growth factor (HGF)‑induced scattering and the metastasis‑inducing HGF/Met signaling pathway in tumor cells and xenograft models. CYR‑61 is a protein that promotes human lung cancer cell metastasis and is closely related to the patient's prognosis in NSCLC. The purpose of the present study was to investigate whether CYR‑61 may serve as a dual potential target for gene therapy of human NSCLC. In the present study, an antibody targeted against CYR‑61 (anti‑CYR‑61) was constructed and the therapeutic effects and underlying mechanism of this antibody in NSCLC cells and mice with NSCLC was investigated. It was observed that NSCLC cell viability, migration and invasion were inhibited while cell apoptosis was induced by the neutralization of CYR‑61 protein by anti‑CYR‑61. Western blotting demonstrated that extracellular signal‑regulated kinase (ERK) and protein kinase B (AKT) expression levels in NSCLC cells were decreased following treatment with anti‑CYR‑61. In addition, it was observed that inhibition of NSCLC cell viability was achieved by the suppression of the epithelial‑mesenchymal transition signaling pathway. ERK and AKT phosphorylation levels were downregulated in NSCLC cells and tumors following anti‑CYR‑61 treatment. Analysis of a murine model indicated that tumor growth was inhibited and tumor metastasis was significantly suppressed (P<0.01) following anti‑CYR‑61 treatment for CYR‑61. In conclusion, CYR‑61 may serve as a potential target for gene therapy for the treatment of human NSCLC.

View Figures

View References

1	Fenton-Ambrose L and Kazerooni EA: Preventative care: Lung-cancer screens now worth the cost. Nature. 514:352014. View Article : Google Scholar : PubMed/NCBI
2	Awad R and Nott L: Radiation recall pneumonitis induced by erlotinib after palliative thoracic radiotherapy for lung cancer: Case report and literature review. Asia Pac J Clin Oncol. 12:91–95. 2016. View Article : Google Scholar : PubMed/NCBI
3	Jiang SY, Zhao J, Wang MZ, Huo Z, Zhang J, Zhong W and Xu Y: Small-cell lung cancer transformation in patients with pulmonary adenocarcinoma: A case report and review of literature. Medicine (Baltimore). 95:e27522016. View Article : Google Scholar : PubMed/NCBI
4	Kong R, Feng J, Ma Y, Zhou B, Li S, Zhang W, Jiang J, Zhang J, Qiao Z, Zhang T, et al: Silencing NACK by siRNA inhibits tumorigenesis in non-small cell lung cancer via targeting Notch1 signaling pathway. Oncol Rep. 35:2306–2314. 2016. View Article : Google Scholar : PubMed/NCBI
5	Brody H: Lung cancer. Nature. 513:S12014. View Article : Google Scholar : PubMed/NCBI
6	Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, et al: Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer. 90:427–432. 2015. View Article : Google Scholar : PubMed/NCBI
7	Barnett SA, Downey RJ, Zheng J, Plourde G, Shen R, Chaft J, Akhurst T, Park BJ and Rusch VW: Utility of routine PET imaging to predict response and survival after induction therapy for non-small cell lung cancer. Ann Thorac Surg. 101:1052–1059. 2016. View Article : Google Scholar : PubMed/NCBI
8	Xie FJ, Lu HY, Zheng QQ, Qin J, Gao Y, Zhang YP, Hu X and Mao W: The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: A meta-analysis. Onco Targets Ther. 9:171–181. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lim SH, Sun JM, Lee SH, Ahn JS, Park K and Ahn MJ: Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opin Biol Ther. 16:397–406. 2016. View Article : Google Scholar : PubMed/NCBI
10	Müller B, Bovet M, Yin Y, Stichel D, Malz M, González-Vallinas M, Middleton A, Ehemann V, Schmitt J, Muley T, et al: Concomitant expression of far upstream element (FUSE) binding protein (FBP) interacting repressor (FIR) and its splice variants induce migration and invasion of non-small cell lung cancer (NSCLC) cells. J Pathol. 237:390–401. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhao Q, Yue J, Zhang C, Gu X, Chen H and Xu L: Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC). Oncotarget. 6:29335–29461. 2015. View Article : Google Scholar : PubMed/NCBI
12	Zhang H, Zhu X, Li N, Li D, Sha Z, Zheng X and Wang H: miR-125a-3p targets MTA1 to suppress NSCLC cell proliferation, migration, and invasion. Acta Biochim Biophys Sin (Shanghai). 47:496–503. 2015. View Article : Google Scholar : PubMed/NCBI
13	Roth MT, Ivey JL, Esserman DA, Crisp G, Kurz J and Weinberger M: Individualized medication assessment and planning: Optimizing medication use in older adults in the primary care setting. Pharmacotherapy. 33:787–797. 2013. View Article : Google Scholar : PubMed/NCBI
14	Lin Y, Xu T, Tian G and Cui M: Cysteine-rich, angiogenic inducer, 61 expression in patients with ovarian epithelial carcinoma. J Int Med Res. 42:300–306. 2014. View Article : Google Scholar : PubMed/NCBI
15	Xu ST, Ding X, Ni QF and Jin SJ: Targeting MACC1 by RNA interference inhibits proliferation and invasion of bladder urothelial carcinoma in T24 cells. Int J Clin Exp Pathol. 8:7937–7944. 2015.PubMed/NCBI
16	Han S, Bui NT, Ho MT, Kim YM, Cho M and Shin DB: Dexamethasone inhibits TGF-β1-induced cell migration by regulating the ERK and AKT pathways in human colon cancer cells via CYR61. Cancer Res Treat. 48:1141–1153. 2016. View Article : Google Scholar : PubMed/NCBI
17	Osaki M, Inaba A, Nishikawa K, Sugimoto Y, Shomori K, Inoue T, Oshimura M and Ito H: Cysteine-rich protein 61 suppresses cell invasion via down-regulation of matrix metalloproteinase-7 expression in the human gastric carcinoma cell line MKN-45. Mol Med Rep. 3:711–715. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hviid CV, Erdem JS, Kunke D, Ahmed SM, Kjeldsen SF, Wang YY, Attramadal H and Aasen AO: The matri-cellular proteins ‘cysteine-rich, angiogenic-inducer, 61’ and ‘connective tissue growth factor’ are regulated in experimentally-induced sepsis with multiple organ dysfunction. Innate Immun. 18:717–726. 2012. View Article : Google Scholar : PubMed/NCBI
19	Ito T, Hiraoka S, Kuroda Y, Ishii S, Umino A, Kashiwa A, Yamamoto N, Kurumaji A and Nishikawa T: Effects of schizophrenomimetics on the expression of the CCN1 (CYR 61) gene encoding a matricellular protein in the infant and adult neocortex of the mouse and rat. Int J Neuropsychopharmacol. 10:717–725. 2007. View Article : Google Scholar : PubMed/NCBI
20	Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas GJ, Born W and Fuchs B: Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res. 27:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
21	Aoki M and Fujishita T: Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189. 2017.PubMed/NCBI
22	Chen X, Cheng H, Pan T, Liu Y, Su Y, Ren C, Huang D, Zha X and Liang C: mTOR regulate EMT through RhoA and Rac1 pathway in prostate cancer. Mol Carcinog. 54:1086–1095. 2015. View Article : Google Scholar : PubMed/NCBI
23	Risolino M, Mandia N, Iavarone F, Dardaei L, Longobardi E, Fernandez S, Talotta F, Bianchi F, Pisati F, Spaggiari L, et al: Transcription factor PREP1 induces EMT and metastasis by controlling the TGF-β-SMAD3 pathway in non-small cell lung adenocarcinoma. Proc Natl Acad Sci USA. 111:E3775–E3784. 2014. View Article : Google Scholar : PubMed/NCBI
24	Bai F, Tian H, Niu Z, Liu M, Ren G, Yu Y, Sun T, Li S and Li D: Chimeric anti-IL-17 full-length monoclonal antibody is a novel potential candidate for the treatment of rheumatoid arthritis. Int J Mol Med. 33:711–721. 2014. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Zhuang T, Djemil T, Qi P, Magnelli A, Stephans K, Videtic G and Xia P: Dose calculation differences between Monte Carlo and pencil beam depend on the tumor locations and volumes for lung stereotactic body radiation therapy. J Appl Clin Med Phys. 14:40112013. View Article : Google Scholar : PubMed/NCBI
27	Lu TS, Yiao SY, Lim K, Jensen RV and Hsiao LL: Interpretation of biological and mechanical variations between the Lowry versus Bradford method for protein quantification. N Am J Med Sci. 2:325–328. 2010.PubMed/NCBI
28	Jang BI and Hwang MJ: Do esophageal squamous cell carcinoma patients have an increased risk of coexisting colorectal neoplasms? Gut Liver. 10:6–7. 2016. View Article : Google Scholar : PubMed/NCBI
29	Kulkarni S, Vella ET, Coakley N, Cheng S, Gregg R, Ung YC and Ellis PM: The use of systemic treatment in the maintenance of patients with non-small cell lung cancer: A systematic review. J Thorac Oncol. 11:989–1002. 2016. View Article : Google Scholar : PubMed/NCBI
30	Yoshiba S, Jansen M, Matsushima N, Chen S and Mendell J: Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors. Cancer Chemother Pharmacol. 77:987–996. 2016. View Article : Google Scholar : PubMed/NCBI
31	Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, Yap TA, Du Y, Vlahos I and deSouza NM: Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. Eur J Cancer. 59:65–78. 2016. View Article : Google Scholar : PubMed/NCBI
32	Rossi A and Di Maio M: Platinum-based chemotherapy in advanced non-small-cell lung cancer: Optimal number of treatment cycles. Expert Rev Anticancer Ther. 16:653–660. 2016. View Article : Google Scholar : PubMed/NCBI
33	Sabile AA, Arlt MJ, Muff R, Husmann K, Hess D, Bertz J, Langsam B, Aemisegger C, Ziegler U, Born W and Fuchs B: Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice. Biochim Biophys Acta. 1832:1173–1182. 2013. View Article : Google Scholar : PubMed/NCBI
34	Chen J, Song Y, Yang J, Gong L, Zhao P, Zhang Y and Su H: The up-regulation of cysteine-rich protein 61 induced by transforming growth factor beta enhances osteosarcoma cell migration. Mol Cell Biochem. 384:269–277. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wong WR, Chen YY, Yang SM, Chen YL and Horng JT: Phosphorylation of PI3K/Akt and MAPK/ERK in an early entry step of enterovirus 71. Life Sci. 78:82–90. 2005. View Article : Google Scholar : PubMed/NCBI
36	Lee YJ, Lee DM and Lee SH: Production of Cyr61 protein is modulated by extracellular acidification and PI3K/Akt signaling in prostate carcinoma PC-3 cells. Food Chem Toxicol. 58:169–176. 2013. View Article : Google Scholar : PubMed/NCBI
37	Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, Franklin RA, Pohnert SC, Mirza AM, McMahon M and McCubrey JA: Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene. 22:2478–2492. 2003. View Article : Google Scholar : PubMed/NCBI